ClinicalTrials.gg
Sign In
Status unknownNCT05080387Updated Feb 15, 2022

Neopterin in Acute Coronary Syndrome Patients

An observational study in Neopterin in Acute Coronary Syndrome Patients, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-02-15.

Sponsored by Assiut University · Observational

The sponsor has not verified this record recently (last verified Oct 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Measurement of neopterin in ACS patients

Read the detailed description
  1. Detect level of neopterin in ACS patients to detect whether there is relation or not between ACS and neopterin
  2. Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS patients
  3. Detect relation between neopterin level and in hospital events
02

Conditions studied

  • Neopterin in Acute Coronary Syndrome Patients
03

In context

Lead sponsor

Assiut University is the lead sponsor of 5,050 studies on the registry; 2,174 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Assiut University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All patients of sample size admitted to cardiology department with ACS.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patient of sample size admitted to cardiology departmentof Assiut university hospital with :

    1. Acute typical chest pain
    2. Positive cardiac enzymes
    3. ECG show recent ischemic changes
    4. ECHO show SWMA

Exclusion criteria

Exclusion Criteria:

  1. Patients not fulfill inclusion criteria.
  2. Patients with other diseases which may cause increase of neopterin level as viral infections, intracellular bacteria or parasites infections, certain malignancies, allograft rejection
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • OtherBlood sample

    Blood samples will obtained for measurement of neopterin level through ELIZA

06

What researchers measure

Primary outcomes

  1. To detect whether there is association between neopterin and ACS or not

    To detect whether there is association between neopterin and ACS or not

    Time frame: 72 hours

Secondary outcomes

  1. Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS and detection of relation between neopterin level and in hospital events

    Detection of relation between neopterin and cardiac enzymes as CK and troponine in ACS and detection of relation between neopterin level and in hospital events

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
  • Assiut university
    Asyut, AssiutU, Egypt
    • Yehia Taha keshik, Prof . Doctor · Contact · 01223971269
    • Magdy Ibrahim El desoky, Lecturer · Contact · 01279950400
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Share if participants agree

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05080387
Lead sponsor
Assiut University
Responsible party
Mina Khairy Alyshaa Gorgy (Mina Khairy Alyshaa Gorgy, Assiut University) — Principal investigator
First posted
Oct 15, 2021
Start date
Nov 1, 2022 (estimated)
Primary completion
Oct 1, 2023 (estimated)
Completion
Oct 1, 2024 (estimated)
Last update
Feb 15, 2022

Study contacts

Mina Khairy Alyshaa Gorgy, Resident
Contact
Minakhairy1995@gmail.com
01227386406
Yehia Taha keshik, Prof. Doctor
Contact
01223971269
Magdy Ibrahim Aldesowky, Lecturer
principal investigator · Assiut University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Assiut University →

Start the discussion